Perspectives on the development of a molecularly targeted agent

Cancer Cell

Volumn 1, Issue 1, 2002, Pages 31-36

  Druker, Brian J ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; IMATINIB; INTERFERON; ANTINEOPLASTIC AGENT; BCR ABL TYROSINE KINASE; BCR-ABL TYROSINE KINASE; ENZYME INHIBITOR; PIPERAZINE DERIVATIVE; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; APOPTOSIS; BONE MARROW SUPPRESSION; CANCER RELAPSE; CELL DEATH; CELL PROLIFERATION; CHROMOSOME ANALYSIS; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DISEASE SEVERITY; DRUG DESIGN; DRUG DOSE REGIMEN; DRUG METABOLISM; DRUG TOLERABILITY; EDEMA; ENZYME ACTIVITY; FLUID RETENTION; GENE EXPRESSION; GENE MUTATION; HUMAN; MUSCLE CRAMP; NAUSEA; NONHUMAN; PATIENT SELECTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN TARGETING; RASH; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; ANIMAL; BINDING SITE; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; DRUG RESISTANCE; ENZYMOLOGY; PHYSIOLOGY; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN TERTIARY STRUCTURE;

ANIMALS; ANTINEOPLASTIC AGENTS; BINDING SITES; CLINICAL TRIALS; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; HUMANS; LEUKEMIA, MYELOID, CHRONIC; PIPERAZINES; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN STRUCTURE, TERTIARY; PROTEIN-TYROSINE KINASES; PYRIMIDINES;

EID: 0036463948     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1535-6108(02)00025-9     Document Type: Review

References (54)

1. Alizadeh, A.A., Eisen, M.B., Davis, R.E., Ma, C., Lossos, I.S., Rosenwald, A., Boldrick, J.C., Sabet, H., Tran, T., Yu, X., et al. (2000). Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403, 503-511.
2. Apperley, J.F., Schultheis, B., Chase, A., Steer, J., Bain, B., Dimitrijevic, S., Marin, D., Olavarria, E., Cross, N., Russell-Jones, R., et al. (2001). Chronic myeloproliferative diseases with t(5;12) and a PDGFRB fusion gene: complete cytogenetic remissions on STI571. Blood 98, 726a.
3. Barthe, C., Cony-Makhoul, P., Melo, J.V., and Mahon, J.R. (2001). Roots of clinical resistance to STI-571 cancer therapy. Science 293, 2163.
4. Blanke, C.D., von Mehren, M., Joensuu, H., Roberts, P.J., Eisenberg, B., Heinrich, M., Druker, B., Tuveson, D., Dimitrijevic, S., Silberman, S.L., and Demetri, G.D. (2001). Evaluation of the safety and efficacy of an oral molecularly-targeted therapy, STI571, in patients with unresectable or metastatic gastrointestinal stromal tumors (GISTS) expressing c-KIT (CD117). Proc. Am. Soc. Clin. Oncol. 20, 1a.
5. Branford, S., Rudzki, Z., Walsh, S., Grigg, A., Arthur, C., Taylor, K., Herrmann, R., Lynch, K., and Hughes, T. (2001). Point mutations clustered within the ATP binding region of Bcr-Abl are common in patients with emerging Glivec resistance but not in Glivec non-responsive cases. Blood 98, 769a.
6. Buchdunger, E., Matter, A., and Druker, B.J. (2001). Bcr-Abl inhibition as a modality of CML therapeutics. BBA Rev. Cancer, in press.
7. Carroll, M., Ohno-Jones, S., Tamura, S., Buchdunger, E., Zimmermann, J., Lydon, N.B., Gilliland, D.G., and Druker, B.J. (1997). CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL and TEL-PDGFR fusion proteins. Blood 90, 4947-4952.
8. Chabner, B.A. (2001). The oncologic four-minute mile. Oncologist 6, 230-232.
9. Daley, G.Q., Van Etten, R.A., and Baltimore, D. (1990). Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247, 824-830.
10. de Klein, A., Geurts van Kessel, A., Grosveld, G., Bartram, C.R., Hagemeijer, A., Bootsma, D., Spurr, N.K., Heisterkamp, N., Groffen, J., and Stephenson, J.R. (1982). A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukemia. Nature 200, 765.
11. Deininger, M.W., Goldman, J.M., Lydon, N., and Melo, J.V. (1997). The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 90, 3691-3698.
12. Deininger, M.W., Goldman, J.M., and Melo, J.V. (2000). The molecular biology of chronic myeloid leukemia. Blood 96, 3343-3356.
13. Dolci, S., Williams, D.E., Ernst, M.K., Resnick, J.L., Brannan, C.I., Lock, L.F., Lyman, S.D., Boswell, H.S., and Donovan, P.J. (1991). Requirement for mast cell growth factor for primordial germ cell survival in culture. Nat. Genet. 352, 809-811.
14. Druker, B.J. (2001). Skeptical scientists. Lancet 358, 11.
15. Druker, B.J., and Lydon, N.B. (2000). Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J. Clin. Invest. 105, 3-7.
16. Druker, B.J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G.M., Fanning, S., Zimmermann, J., and Lydon, N.B. (1996). Effects of a selective inhibitor of the ABL tyrosine kinase on the growth of BCR-ABL positive cells. Nat. Med. 2, 561-566.
17. Druker, B.J., Sawyers, C.L., Kantarjian, H., Resta, D.J., Fernandes Reese, S., Ford, J.M., Capdeville, R., and Talpaz, M. (2001a). Activity of a specific inhibitor of the Bcr-Abl tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 344, 1038-1042.
18. Druker, B.J., Talpaz, M., Resta, D., Peng, B., Buchdunger, E., Ford, J.M., Lydon, N.B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., and Sawyers, C.L. (2001b). Efficacy and safety of a specific inhibitor of the Bcr-Abl tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344, 1031-1037.
19. Faderl, S., Talpaz, M., Estrov, Z., and Kantarjian, H.M. (1999). Chronic myelogenous leukemia: biology and therapy. Ann. Intern. Med. 131, 207-219.
20. Gambacorti-Passerini, C., le Coutre, P., Mologni, L., Fanelli, M., Bertazzoli, C., Marchesi, E., Di Nicola, M., Biondi, A., Corneo, G.M., Belotti, D., et al. (1997). Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis. Blood Cells Mol. Dis. 23, 380-394.
21. Goldman, J.M., and Druker, B.J. (2001). Chronic myeloid leukemia: Current treatment options. Blood, in press.
22. Golub, T.R., Barker, G.F., Lovett, M., and Gilliland, D.G. (1994). Fusion of PDGR receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 77, 307-316.
23. Gorre, M.E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P.N., and Sawyers, C.L. (2001). Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293, 876-880.
24. Graham, S.M., Jorgensen, H.G., Allan, E., Pearson, C., Alcorn, M.J., Richmond, L., and Holyoake, T.L. (2001). Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 99, 319-325.
25. Groffen, J., Stephenson, J.R., Heisterkamp, N., de Klein, A., Bartram, C.R., and Grosveld, G. (1984). Philadelphia chromosome breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 36, 93-99.
26. Heinrich, M., Blanke, C.D., Druker, B.J., and Corless, C.L. (2002). Inhibition of KIT tyrosine kinase activity: A novel molecular approach to the treatment of KIT positive malignancies. J. Clin. Oncol., in press.
27. Heisterkamp, N., Stephenson, J.R., Groffen, J., Hansen, P.F., de Klein, A., Bartram, C.R., and Grosveld, G. (1983). Localization of the c-abl oncogene adjacent to a translocation break point in chronic myelocytic leukemia. Nature 306, 239-242.
28. Heisterkamp, N., Jenster, G., ten Hoeve, J., Zovich, D., Pattengale, P.K., and Groffen, J. (1990). Acute leukaemia in bcr/abl transgenic mice. Nature 344, 251-253.
29. Hochhaus, A., Kreil, S., Muller, M.C., Lahaye, T., La Rosse, P., Corbin, A.S., Schoch, C., Cross, N.C.P., Berger, U., Reider, H., et al. (2001). Molecular and chromosomal mechanisms of resistance in CML patients after STI571 (Glivec) therapy. Blood 98, 435a.
30. Huettner, C.S., Zhang, P., Van Etten, R.A., and Tenen, D.G. (2000). Reversibility of acute B-cell leukaemia induced by BCR-ABL1. Nat. Genet. 24, 57-60.
31. Kantarjian, H.M., Sawyers, C.L., Hochhaus, A., Guilhot, F., Schiffer, C.A., Deininger, M.W., Gambacorti-Passerini, C., Stone, R.M., Goldman, J.M., Fischer, T., et al. (2001). Gleevec (imatinib mesylate) induced hematologic and cytogenetic responses confirmed and expanded in patient's with chronic myeloid leukemia (CML) - a phase II study update. Blood 98, 845a.
32. Kelliher, M.A., McLaughlin, J., Witte, O.N., and Rosenberg, N. (1990). Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL. Proc. Natl. Acad. Sci. USA 87, 6649-6653.
33. Konopka, J.B., Watanabe, S.M., and Witte, O.N. (1984). An alteration of the human c-abl protein in K562 unmasks associated tyrosine kinase activity. Cell 37, 1035-1042.
34. Lugo, T.G., Pendergast, A.M., Muller, A.J., and Witte, O.N. (1990). Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 247, 1079-1082.
35. Mauro, M.J., O'Dwyer, M., Heinrich, M.C., and Druker, B.J. (2002). STI571: a paradigm of new agents for cancer therapeutics. J. Clin. Oncol. 20, 325-334.
36. Nowell, P.C., and Hungerford, D.A. (1960). A minute chromosome in human chronic granulocytic leukemia. Science 132, 1497-1501.
37. Peng, B., Hayes, M., Racine-Poon, A., Druker, B.J., Talpaz, M., Sawyers, C.L., Resta, D., Ford, J.M., Lloyd, P., and Capdeville, R. (2001). Clinical investigation of the pharmacokinetic/pharmacodynamic relationship for Glivec (STI571): a novel inhibitor of signal transduction. Proc. Am. Soc. Clin. Oncol. 20, 280a.
38. Rowley, J.D. (2001). Chromosome translocations: dangerous liaisons revisited. Nat. Rev. Cancer. 1, 245-250.
39. Rowley, J.D. (1973). A new consistent abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and giemsa staining. Nature 243, 290-293.
40. Russell, E.S. (1979). Hereditary anemias of the mouse: A review for geneticists. Adv. Genet. 20, 357-359.
41. Sacchi, S., Kantarjian, H.M., O'Brien, S., Cortes, J., Rios, M.B., Giles, F.J., Beran, M., Koller, C.A., Keating, M.J., and Talpaz, M. (1999). Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients. Cancer 86, 2632-2641.
42. Sawyers, C.L. (1999). Chronic myeloid leukemia. N. Engl. J. Med. 340, 1330-1340.
43. Sawyers, C.L., Hochhaus, A., Feldman, E., Goldman, J.M., Miller, C., Ottman, O.G., Schiffer, C.A., Talpaz, M., Guilhot, F., Niederwieser, D., et al. (2001). Gleevec/Glivec (imatinib mesylate, STI571) in patients with chronic myeloid leukemia (CML) in myeloid blast crisis: updated results of a phase II study. Blood 98, 845a.
44. Schindler, T., Bornmann, W., Pellicena, P., Miller, W.T., Clarkson, B., and Kuriyan, J. (2000). Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289, 1938-1942.
45. Schwartzberg, P.L., Stall, A.M., Hardin, J.D., Bowdish, K.S., Humaran, T., Boast, S., Harbison, M.L., Robertson, E.J., and Goff, S.P. (1991). Mice homozygous for the ablm1 mutation show poor viability and depletion of selected B and T cell populations. Cell 65, 1165-1175.
46. Shah, N.P., Nicoll, J.M., Gorre, M.E., Paquette, R.L., Ford, J.M., and Sawyers, C.L. (2001). Resistance to Gleevec: sequence analysis reveals a spectrum of Bcr/Abl kinase domain mutations in both acquired and de novo resistant cases of chronic myelogenous leukemia in blast crisis. Blood 98, 770a.
47. Shipp, M.A., Tamayo, P., Angelo, M., Ray, T., Reich, M., Neuberg, D., Last, K., Aster, J., Mesirov, J., Lister, A., and Golub, T.R. (2000). Diffuse large B cell lymphoma outcome prediction by gene expression profiling. Blood 96, 222a.
48. Shtivelman, E., Lifshitz, B., Gale, R.P., and Canaani, E. (1985). Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature 315, 550-554.
49. Soriano, P. (1994). Abnormal kidney development and hematological disorders in PDGF β-receptor mutant mice. Genes Dev. 8.
50. Soriano, P. (1997). The PDGF alpha receptor is required for neural crest cell development and for normal patterning of the somites. Development 124, 2691-2700.
51. Talpaz, M., Silver, R.T., Druker, B.J., Paquette, R., Goldman, J.M., Gambacorti-Passerini, C., Guilhot, F., Schiffer, C.A., Reese, S.F., Kantarjian, H.M., and Ford, J.M. (2001). Gleevec (formerly STI571): an active drug in patients with Ph+ chronic myeloid leukemia in accelerated phase - updated results of a phase II study. Blood 98, 845a.
52. Tybulewicz, V.L., Crawford, C.E., Jackson, P.K., Bronson, R.T., and Mulligan, R.C. (1991). Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene. Cell 65, 1153-1163.
53. van Oosterom, A.T., Judson, I., Verweij, J., Stroobants, S., Donato di Paola, E., Dimitrijevic, S., Martens, M., Webb, A., Sciot, R., Van Glabbeke, M., et al. (2001). Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 358, 1421-1423.
54. Von Hoff, D.D., and Bootman, J.L. (2001). A standing ovation for a change in how we treat patients with cancer - forever. Oncology Spectrums 2, 375.